Evolving Role of Radiation in Polymetastatic Disease

This webinar will provide a practical medical physics perspective on implementing SBRT for polymetastatic disease. Key topics will include CT simulation and imaging strategies, motion management, multi-isocenter treatment planning, composite plan evaluation, and treatment delivery considerations. Drawing on practical examples and lessons learned
from the ARREST and ARREST-2 trials, the presentation will highlight how structured multidisciplinary communication, quality assurance checkpoints, and adaptive decision-making can support safe, efficient, and high-quality treatment delivery.
The presentation will also review the clinical rationale for extending SABR to polymetastatic disease, examine emerging evidence from the ARREST studies, and discuss practical
considerations for safely implementing these complex treatments. Topics will include patient selection based on technical feasibility rather than lesion count alone, multidisciplinary workflow, simulation and treatment delivery strategies, organ-at-risk–driven decision making, and planning approaches that enable treatment of numerous metastases while maintaining safety. Attendees will gain practical insights into how comprehensive SABR can be incorporated into clinical practice and how lessons from the ARREST program are informing the ongoing international ARREST-2 trial.

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiologists, pathologists, surgeons, researchers, oncologists and allied healthcare professionals interested in ablative radiation therapy for cancer treatment.

Learning Objectives

At the conclusion of this activity, the participant will be able to:

  • Identify practical strategies for CT simulation, motion management, treatment planning, composite plan evaluation, and treatment delivery in patients with polymetastatic disease.
  • Describe the technical and logistical challenges involved in implementing SBRT for polymetastatic disease across multiple anatomic sites.
  • Discuss how structured workflows, multidisciplinary communication, and quality assurance processes can support safe and efficient delivery of SBRT for polymetastatic disease.
  • Identify patients with polymetastatic disease who are appropriate candidates for comprehensive SABR based on technical feasibility and organ-at-risk constraints rather than lesion count.
  • Describe key workflow elements required for the safe implementation of comprehensive SABR.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
07/24/2026
Course expires: 
09/10/2028
Cost:
$0.00
Rating: 
0

Moderator:  

  • Bhanu Prasad Venkatesulu, MD, MBBS, is employed by University of Pittsburgh Medical Center. Dr. Venkatesulu owns stock in ImmunityBio and Spectrum Pharmaceuticals. 

Speakers: 

 

  • Hatim Fakir, PhD, MCCPM, is employed by the London Health Sciences Centre. Dr. Fakir is the founder, director and has ownership equity in PrecisionXRT.
  • Timothy Nguyen, MD, is employed by the London Health Sciences Centre. Dr. Nguyen has no relevant financial relationship with ineligible companies to disclose.
  • Melissa O'Neil, MSc., MRT(T), is employed by the London Health Sciences Centre. Ms. O'Neil has no relevant financial relationship with ineligible companies to disclose.  

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.